ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bone density"

  • Abstract Number: 2563 • ACR Convergence 2024

    Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial

    Jean-Yves Reginster1, Stuart L. Silverman2, Edward Czerwinski3, Przemyslaw Borowy4, Tomasz Budlewski5, Joanna Kwiatek6, Svitlana Postol7, Airi Põder8, Jerzy Supronik9, SungHyun Kim10, JeeHye Suh10, GoEun Yang10, NooRi Han10, NaHyun Kim10 and SeoHee Bae10, 1Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, 2OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, 3Krakow Medical Centre, Kraków, Poland, 4Krakowskie Centrum Medyczne, Krakow, Poland, 5Department of Rheumatology, Medical University of Lodz, Lodz, Poland, 6Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, 7Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, 8Clinical Research Centre Ltd, Tartu, Estonia, 9Osteo-Medic s.c., Białystok, Poland, 10Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
  • Abstract Number: 1616 • ACR Convergence 2024

    Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis

    Gaston Ariel Ghio1, Marta Domínguez-Álvaro2, Ricardo Blanco-Alonso3, Santos Castañeda4, Iñigo Hernández-Rodríguez5, Elisa Fernández-Fernández:6, Maite Silva-Diaz7, Joaquin María Belzunegui:8, Clara Moriano9, Julio Sánchez-Martín10, Javier Narvaez-García11, Eva Galindez12, Anne Riveros Frutos13, Francisco Ortiz Sanjuán14, Tarek Carlos Salman Monte:15, Margarida Vasques Rocha:16, Carlota L Iñiguez:17, Alicia García Dorta18, Clara Molina Almela19 and María Alcalde Villar:20, and ARTESER Project Collaborative Group, 1Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 6La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 7Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 8H de Donostia, Donostia-San Sebasti, Spain, 9Hospital León, LEON, Spain, 10Hospital Universitario 12 de Octubre, Madrid, Spain, 11Hospital Universitario de Bellvitge, Barcelona, Spain, 12Hospital Universitario de Cabueñes, Bilbao, Spain, 13Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 14Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, 15Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 16Hospital Universitario Araba, Vitoria, Spain, 17Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 18Rheumatologist, La Laguna, Spain, 19Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 20Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain

    Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
  • Abstract Number: 2114 • ACR Convergence 2024

    CT and DXA Bone Fragility Evaluation After Bariatric Surgery

    Marine FAUNY1, Marion Halin2, Edem Allado2, Laurent Brunaud2, Claire Nomine Criqui2, Eliane Albuisson2, Isabelle Chary-Valckenaere3, Damien Loeuille4 and Didier Quilliot2, 1CH TOUL, Toul, Lorraine, France, 2Nancy University Hospital, Vandoeuvre, Lorraine, France, 3Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, 4Phd, Nancy Vandoeuvre, Lorraine, France

    Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…
  • Abstract Number: 2118 • ACR Convergence 2024

    Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis

    Yen-An Chang1 and Ming‑Han Chen2, 1Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan

    Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis.  Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
  • Abstract Number: 2119 • ACR Convergence 2024

    IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures

    Chloe Heiting1, Donald McMahon1, Douglas Mintz1, Weijia Yuan1, Insa Mannstadt1, Linda A Russell1, Emily Stein1, Dalit Ashany2 and Susan Goodman3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Scarsdale, NY, 3Hospital for Special Surgery, New York 10025, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
  • Abstract Number: 2120 • ACR Convergence 2024

    EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry

    BEATRIZ ROSA1, Melissa Fraga1, Erica Barbosa1, Jade Dib Fernandez2, Marcelo Pinheiro3 and Maria Teresa Terreri4, 1Universidade Federal de São Paulo, São Paulo, SP, Brazil, 2UNIFESP-EPM, São Paulo, SP, Brazil, 3UNIFESP/ EPM, São Paulo, SP, Brazil, 4UNIFESP, São Paulo, SP, Brazil

    Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
  • Abstract Number: 2125 • ACR Convergence 2024

    Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores

    Ana Rodriguez-Flores1, Ana Cecilia Bardan-Inchaustegui2, Mara Ponce2, Galilea Rodriguez3, Anahí Carrazco Chapa4, Valeria Monserrat De Hoyos-Perez5, Gilberto J Cervantes Charles5, Alma Damian Peñaloza5, Cinthia Maribel Cortez Lopez5, CASSANDRA SKINNER TAYLOR6, Roberto Negrete Lopez5, Jesus Cardenas-de la Garza2 and Dionicio Galarza-Delgado7, 1Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, 4Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, 5Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 6HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of fractures due to factors such as chronic inflammation, use of glucocorticoids, and reduced muscle mass.…
  • Abstract Number: 2126 • ACR Convergence 2024

    Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study

    Carmen Gomez Vaquero1, Marta Domínguez-Álvaro2, Daniel Seoane-Mato3, Pilar Peris4, Santos Castañeda5, Eduardo Kanterewicz Binstock6, Ramon Mazzucchelli7, Luis Arboleya8, Miguel Bernad9, Antonio Alvarez-Cienfuegos10, Blanca Correa11, Luis-Maria Jimenez-Liñan12, Carmen Mateo-Pascual13, Mª Mercedes Molina del Rio14, Mercedes Retamal-Ortiz15, Aida Fatima Lopez-Laguna16, Ruth Molera-Valero17, Sara Alvar-Pariente18, Antonio Pascual19, Adolfo Arias-Senso20, Nuria Perez-Gutierrez21, Soledad Garcia-Frias22, David Bouza-Alvarez23, Susana Sostres24, Daniel Suarez-Hernandez25, Ana Zamora-Casal26, Cristina Garcia-Ramirez27 and Enrique González-Dávila28, and OsteoSER Project Collaborative Group, 1Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Catalonia, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Madrid, Spain, 4Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Universitari de Vic (Consorci Hospitalari de Vic), Barcelona, Spain, 7Hospital Universitario Fundacion Alcorcon, Madrid, Spain, 8Hospital Universitario Central de Asturias, Oviedo, Spain, 9Hospital Universitario La Paz, Madrid, Spain, 10Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain, 11Clínica Sanz y Correa, A Coruña, Spain, 12Hospital Don Benito-Villanueva, Don Benito, Spain, 13Centro de Salud Fuencarral, distrito Fuencarral-El Pardo, Madrid, Spain, 14Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, 15Centro de Salud Don Benito Oeste, Don Benito, Spain, 16Centro de Salud El Molar, El Molar, Spain, 17Centro de Salud Orihuela 1-El Rabaloche, Orihuela, Spain, 18Centro de Salud Malpica, Malpica, Spain, 19Centro de salud Ronda-Norte y Ronda-Sur Santa Bárbara, Ronda, Spain, 20Centro de Salud de Santa Amalia, Santa Amalia, Spain, 21Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, 22Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, 23Centro de Salud Elviña Mesoiro, A Coruña, Spain, 24Centro de Atención Primaria Cap 17 de setembre, El Prat de Llobregat, Spain, 25Centro de Salud de Benejuzar, Benezujar, Spain, 26Centro de Salud Os Mallos, A Coruña, Spain, 27Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, 28Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain

    Background/Purpose: The bone mineral density (BMD) reference data for the Spanish population comes from the study Multicentre Research Project on Osteoporosis (MPRO), concluded in 1989.Our…
  • Abstract Number: 2127 • ACR Convergence 2024

    Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population

    Isabella Silvestre Ignarro1, Gabriela Tieme Ochikubo2, Liliam Takayama3, Valeria de falco Caparbo2, Camille Pinto Figueiredo2, Marcos Rafael Nogueira Cavalcanti1, Angelita Gomes De Souza1, Isabela Judith Martins Bensenor1, Ricardo Fuller1 and Diogo Domiciano4, 1Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 2Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, 3Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil

    Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…
  • Abstract Number: 2129 • ACR Convergence 2024

    Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies

    Thiago Quadrante Freitas1, Leonardo Olalla2, Luana Machado3, Camille Figueiredo3, Liliam Takayama4, Valeria Caparbo3, Ricardo Oliveira5, Diogo Domiciano1 and Rosa M R Pereira3, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Quito, Ecuador, 3Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, SP, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5RDO DIAGNÓSTICOS MÉDICOS, São Paulo, SP, Brazil

    Background/Purpose: The World Health Organization Fracture Risk Assessment Tool (FRAX®) was developed to estimate the 10-year absolute probability of osteoporotic fractures among the general population.…
  • Abstract Number: 2133 • ACR Convergence 2024

    Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better

    Zeqin Wen1, Yilun Wang1, Xiaoxiao Li2, Yuqing Zhang3, Junqing Xie4, Houchen Lyu5, Changjun Li2, Jie Wei6, Guanghua Lei7 and Chao Zeng8, 1Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), 2Central South University, Changsha, China (People's Republic), 3Massachusetts General Hospital, Quincy, MA, 4University of Oxford, Oxford, United Kingdom, 5Central South University, Beijing, China, 6Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), 7Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), 8Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic)

    Background/Purpose: High low-density lipoprotein cholesterol (LDL-C) is a major risk factor for fracture; however, whether LDL-C lowering induced by statins is associated with decreased fracture…
  • Abstract Number: 0860 • ACR Convergence 2023

    Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation

    Chandramohan Natarajan1, Julia Lucchino1, David Chenoff2 and Yaakov Levine1, 1SetPoint Medical, Valencia, CA, 2SetPoint Medical, Sausalito, CA

    Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
  • Abstract Number: 1185 • ACR Convergence 2023

    Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients

    Tine Vanhaverbeke1, Dirk Elewaut2 and Ruth Wittoek1, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, 2Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: In osteoporotic patients, discontinuation of denosumab is associated with a rapid increase in bone turnover and bone loss. Denosumab was recently proven to have…
  • Abstract Number: 1996 • ACR Convergence 2023

    Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

    Karla Miller1, Melissa Steffen2, Kimberly McCoy2, Michelle Mengeling2, Heather Davila2, Shylo Wardyn2 and Samantha Solimeo2, 1University of Utah School of Medicine, Salt Lake City, UT, 2Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA

    Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
  • Abstract Number: 1997 • ACR Convergence 2023

    A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

    Richard Eastell1, Bente Langdahl2, Yoon-Sok Chung3, Rafal Plebanski4, Edward Czerwinski5, Eva Dokoupilova6, Jerzy Supronik7, Jan Rosa8, Anna Rowińska-Osuch9, Ki-Hyun Baek10, Audrone Urboniene11, Sohui Ahn12, Younghee Rho12 and Jisuk Ban12, 1University of Sheffield, Sheffield, United Kingdom, 2Aarhus University Hospital, Aarhus, Denmark, 3Ajou University Hospital, Suwon, South Korea, 4Klinika Zdrowej Kosci, Łódź, Poland, 5Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, 6Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 7OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, 8Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, 9ETG Warszawa, Warszawa, Poland, 10Yeouido ST. Mary's Hospital, Seoul, South Korea, 11JSC Saules seimos medicinos centras, Kaunas, Lithuania, 12Samsung Bioepis, Incheon, South Korea

    Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology